无锡祥生医疗科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688358 证券简称：祥生医疗 无锡祥生医疗科技股份有限公司 2024 年年度股东大会会议须知 无锡祥生医疗科技股份有限公司 2024 年年度股东大会 会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保 证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 二〇二五年五月 1 无锡祥生医疗科技股份有限公司 2024 年年度股东大会会议资料 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等 权利。股东及股东代理人参加股东大会应认真履行其法定义务，不得侵犯公司 和其他股东及股东代理人的合法权益，不得扰乱股东大会的正常秩序。 五、股东及股东代理人要求在股东大会现场会议上发言的，应于股东大会 召开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序 安排发言。 现场要求提问的股东及股东代理人，应当按照会议的议程举手示意，经会 议主持人许可后方可提问。有多名股东及股东代理人同时要求提问时，先举手 者先提问；不能确定先后时，由主持人指定提问者。 会议进行中只接受股东及股东代理人 ...

Group 1 - The core stock price of Xiangsheng Medical (688358) closed at 28.78 yuan on April 30, 2025, with an increase of 2.53% and a trading volume of 1.09 million shares, resulting in a transaction amount of 31.428 million yuan [1] - The company has made significant advancements in AI-assisted diagnostic software across various medical fields, including breast diseases, carotid arteries, thyroid, obstetrics, liver, and heart [2] - On April 30, 2025, the net capital flow for Xiangsheng Medical showed a net outflow of 76.25 thousand yuan from main funds, a net outflow of 49.76 thousand yuan from speculative funds, while retail investors had a net inflow of 126.01 thousand yuan [2] Group 2 - The company is committed to continuous technological and product innovation, aiming to accelerate the integration of AI technology in ultrasound medical imaging and diagnosis [2] - The capital flow analysis indicates that main funds accounted for 2.43% of the total transaction amount, speculative funds accounted for 1.58%, and retail investors represented 4.01% [2]

Group 1: Company Insights - BGI Genomics faces challenges such as declining demand, operational complexity, and high prices in the genetic testing industry, but is enhancing efficiency through automation and AI, while expanding into reproductive health and cancer prevention [1] - Nanshan Zhishang reported a 12.84% year-on-year increase in net profit for Q1, driven by new materials business, particularly ultra-high molecular weight polyethylene fibers [2] - Jizhi Co. saw a 54.89% increase in revenue year-on-year in Q1, benefiting from stable growth in balancing machine sales and automation line revenue [3] - Huangma Technology's export sales grew over 30% in Q1 2025, with improved gross margins due to increased production and lower raw material costs [4] - Proya Cosmetics aims to become the first beauty company in China to exceed 10 billion in revenue by 2024, focusing on expanding its product matrix and enhancing online and offline channels [5] - Daotong Technology is advancing its "embrace AI" strategy, significantly enhancing its digital repair and energy products, with a 60% growth in its TPMS series [6] - Lianchuang Optoelectronics experienced significant revenue growth in Q1 2025, with a focus on optimizing asset quality in the backlight source industry [7] - Hengshuai Co. reported a 16.04% decline in revenue for Q1 2025, facing challenges in traditional cleaning and motor businesses, but is expanding its ADAS cleaning system business [8] - Weifeng Electronics achieved a 9.77% revenue growth in 2024, despite a decline in net profit due to reduced non-operating income and increased expenses [9] - Perfect World continues to enhance its gaming portfolio with successful updates and expansions, including the launch of new titles and esports initiatives [11] - Xiangsheng Medical invested 80 million in R&D in 2024, focusing on AI technology in ultrasound products and maintaining a strong dividend policy [12] - Jiuhua Tourism reported a 30.13% revenue increase in Q1 2025, driven by a rise in tourist visits and ongoing infrastructure projects [13] - Jingzhida's semiconductor business line saw a revenue share increase to over 70% in Q1 2025, with ongoing efforts to localize core components [14] - Teruid's management outlined plans for international expansion and the development of a virtual power plant platform to enhance service offerings [15] Group 2: Industry Trends - The genetic testing industry is experiencing increased competition and cost pressures, prompting companies to innovate and optimize operations [1] - The new materials sector is becoming a key growth driver, particularly in high-performance fibers used in various applications [2] - Automation and AI are reshaping traditional manufacturing and service sectors, enhancing efficiency and product offerings [3][6] - The beauty and cosmetics industry is focusing on market expansion and product diversification to capture a larger share of the global market [5] - The gaming industry is evolving with continuous updates and new releases, indicating a strong demand for innovative gaming experiences [11] - The tourism sector is recovering with increased visitor numbers, highlighting the importance of infrastructure development and service enhancement [13]

Investment Rating - The investment rating for Xiangsheng Medical (688358) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on revenue growth and product development [1]. Core Viewpoints - The company reported a revenue of 469 million yuan in 2024, a year-over-year decrease of 3.13%, with a net profit of 141 million yuan, down 4.08% year-over-year. However, cash flow from operating activities increased significantly by 63.76% to 141 million yuan [1][2]. - The company maintains a stable gross margin of 58.95% in 2024, slightly up from the previous year, attributed to an increase in domestic sales and changes in product structure [2]. - Research and development efforts are focused on AI advancements, enhancing the competitiveness of portable ultrasound products, and addressing clinical pain points with innovative solutions [2]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 469 million yuan, with ultrasound imaging equipment contributing 427 million yuan and accessories generating 30.4 million yuan, reflecting a 20.45% increase year-over-year [2]. - The company’s gross margin for 2024 was 58.95%, showing a slight increase of 0.14 percentage points year-over-year [2]. - The forecast for revenue from 2025 to 2027 is 549 million yuan, 664 million yuan, and 801 million yuan, with respective year-over-year growth rates of 17.0%, 21.0%, and 20.8% [2][4]. Research and Development - R&D expenses reached 79.63 million yuan in 2024, representing 16.99% of total revenue, indicating a strong commitment to innovation [2]. - The company has made significant progress in AI-assisted diagnostic software across various medical fields, enhancing the accuracy and efficiency of screenings [2]. Market Position and Strategy - The company is actively expanding its market presence, particularly in the domestic sector, benefiting from government policies aimed at upgrading medical equipment [2]. - The report highlights the company's strategic focus on portable ultrasound technology, which is expected to drive future growth and customer acquisition [2].

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 祥生医疗(688358) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 三季度业绩持续增长，股权激励彰显 信心 公司发布股权激励，分段目标彰显信 心 核心产品认可度提升，H1 放量驱动业 绩增长 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B座 邮编：100031 [Table_Title] 毛利率保持稳定，AI 赋能加速市场拓展 [Table_ReportDate] 2025 年 04 月 28 日 [Table_S 事件：公司发布 ummary] 2024 年年报和 2025 年一季报，2024 年公司实现营业收入 4.69 亿元（yo ...

4月27日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者参 考。 【品大事】 海源复材：公司股票自4月29日起实行退市风险警示 海源复材(002529)晚间公告，公司股票将于2025年4月28日停牌一天，自4月29日起被实行"退市风险警 示"特别处理，股票简称变更为"*ST海源"，日涨跌幅限制为5%。 新莱福：拟购买金南磁材100%股份 股票28日复牌 新莱福(301323)晚间公告，公司拟筹划发行股份及支付现金购买广州金南磁性材料有限公司（简称"金 南磁材"）100%股份并募集配套资金暨关联交易事项，本次交易预计构成重大资产重组。公司股票将于 2025年4月28日开市起复牌。本次交易完成后，公司将通过整合金南磁材在永磁材料、软磁材料及PM粉 末冶金领域的核心技术优势，实现业务边界的战略性拓展与产业链深度协同。 红宝丽：子公司聚氨酯公司聚醚技术改造项目试生产成功 红宝丽(002165)晚间公告，子公司聚氨酯公司聚醚技术改造项目已建设完工并试生产成功，产出单体聚 醚、组合聚醚和特种聚醚合格产品。 星光股份：公司及相关人员收到广东证监局警示函 星光股份(002076)晚间公告，公 ...

格隆汇4月27日丨祥生医疗(688358.SH)公布，因股东自身资金需求及资金规划，公司股东无锡祥鼎投资 企业（有限合伙）、拟自本减持计划公告披露之日起15个交易日后的3个月内，通过集中竞价或大宗交 易的方式减持合计不超过所持公司股份1,176,000股,即不超过祥生医疗总股本的1.05%。其中以集中竞价 方式拟减持股份数量为合计不超过701,256股，即不超过祥生医疗总股本的0.63%；以大宗交易方式拟减 持股份数量为合计不超过474,744股，即不超过祥生医疗总股本的0.42%。 因股东自身资金需求及资金规划，公司股东上海御德科技有限公司拟自本减持计划公告披露之日起15个 交易日后的3个月内，通过集中竞价的方式减持合计不超过所持公司股份419,989股,即不超过公司总股本 的0.37%。 因股东自身资金需求及资金规划，公司股东无锡祥鹏投资企业（有限合伙）拟自本减持计划公告披露之 日起15个交易日后的3个月内，通过集中竞价的方式减持合计不超过所持公司股份336,000股,即不超过公 司总股本的0.30%。 上述股东减持价格将根据减持时的市场价格确定；若在减持计划实施期间公司发生送股、资本公积转增 股本、配股 ...

Core Viewpoint - Xiangsheng Medical has demonstrated significant advancements in AI-assisted ultrasound diagnostics, showcasing a strong financial performance and a robust innovation pipeline in the healthcare sector [1][2][3] Financial Performance - In Q1 2025, the company reported revenue of 128 million yuan and a net profit of 41.61 million yuan attributed to shareholders [1] Technological Advancements - The company has made breakthroughs in AI-assisted diagnostic software across multiple specialties, with a notable achievement being the breast ultrasound analysis software, which received medical device registration in 2022 [2] - As of the end of 2024, the company holds a total of 61 core technologies, reflecting its leading position in independent innovation within the industry [2] Research and Development - In 2024, the company invested 79.63 million yuan in R&D, accounting for 16.99% of its revenue, with R&D personnel making up 34.64% of its workforce [2] - The company secured 48 new patent authorizations in 2024, including 30 invention patents, and filed 66 intellectual property applications [2] Product Development - The company launched the SonoFamily series in 2024, which includes various high-end ultrasound products, enhancing its market offerings [3] - In 2024, the company obtained 5 domestic market access licenses and 35 international market access licenses, expanding its global presence [3] Market Positioning - Driven by domestic policy benefits and global market demand, the company is solidifying its leadership in the specialty ultrasound field, with a focus on the deep application of medical AI to accelerate industry transformation [3]

证券代码：688358 证券简称：祥生医疗 公告编号：2025-015 无锡祥生医疗科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ⚫ 本次减持股东的基本情况 截至本公告披露日，无锡祥生医疗科技股份有限公司（以下简称"公司"）股 东无锡祥鼎投资企业（有限合伙）（以下简称"祥鼎投资"）持有公司股份 4,704,000 股，占公司总股本的 4.20%；股东上海御德科技有限公司（以下简称"上海御德"） 持有公司股份 1,679,956 股，占公司总股本的 1.50%；股东无锡祥鹏投资企业（有 限合伙）（以下简称"祥鹏投资"）持有公司股份 1,344,000 股，占公司总股本的 1.20%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公 司实施资本公积转增股本取得的股份，涉及公司首次公开发行前取得的股份已于 2022 年 12 月 3 日解除限售并上市流通。 ⚫ 减持计划的主要内容 因股东自身资金需求及资金规划，公司股东无锡祥鼎投资企业（有限 ...

同日晚间，祥生医疗发布2024年度分红预案，公司拟向全体股东每10股派发现金股利10元（含税），合计派发现金红利 1.12亿元（含税），占公司当年度合并报表归属上市公司股东净利润的比例为79.62%。Wind资讯数据显示，自2019年上市以 来，祥生医疗平均分红率61.71%，累计分红金额达4.64亿元，彰显公司对未来高质量发展的坚定信心。 祥生医疗相关工作人员表示，公司将继续积极适应行业趋势，坚定不移走自主研发创新发展之路，基于超声医学影像具有 良好的市场增长空间和较高的技术壁垒，结合公司超声核心技术的沉淀与积累，重点布局于高端彩超、便携小型化彩超、专科 彩超和超声人工智能等多个方面。 （编辑 张钰鹏） 报告期内，祥生医疗加快国内外产品注册进程。2024年，公司新增国内市场准入许可5项，涵盖智能超声设备、全球首个 最轻最薄笔记本超声设备等独特的系列产品；国内市场准入许可35项，覆盖欧洲、中东、美洲、非洲等多个国家和地区。 创新始终是祥生医疗高质量发展的"底色"。2024年，祥生医疗研发投入7963.39万元，同比增长3.32%，占营业收入比重为 16.99%。截至2024年12月底，祥生医疗累计拥有发明专利 ...